MRNA, which rose 177% in one day, is still short squeeze after revaluation

NEXT PICK · Market Insights

MRNA, which rose 177% in one day, is still short squeeze after revaluation

Wednesday, August 19, 2026

A large-cap biotech stock with a market value of over $20 billion rose 176.97% at a typical Wednesday close, ending at $174.38, compared to just $62.96 the previous day—this isn't a limit-up game for small-cap stocks, but Moderna, a company that has suffered huge losses for three consecutive years, with revenue shrinking by 90% from its peak.

What drives it is a truly historic message

The personalized mRNA cancer vaccine intismeran autogene, developed in collaboration with Merck, achieved the primary endpoint in the Phase III INTerpath-001 trial, marking the first Phase III success in mRNA cancer therapy.

But on the same day, the stock's closing price surpassed all published targets on Wall Street and nearly three times its own 50-day moving average, and the detailed efficacy data underlying this celebration has yet to be disclosed.

Latest price $174.38 ▲ +176.97%

Market capitalization 69.62 billion USD ▲ An increase of about 45 billion yuan in one day

Empty heads occupy the circulation 13.5% ▼ A daily floating loss of about 4.8 billion yuan

A company that relies on three legs has only one leg that has ever truly made money

Moderna is headquartered in Cambridge, Massachusetts, with its business spread across three areas: respiratory vaccines, oncology treatments, and rare and bacterial disease vaccines.

The respiratory tract segment is the source of its entire revenue today, including the COVID-19 vaccine Spikevax, RSV vaccine mRESVIA, the next-generation COVID vaccine mNEXSPIKE, and the seasonal flu vaccine mFLUSIVA, which just received FDA approval on August 5.

But the numbers in this segment are not impressive. Full-year revenue for 2025 is $1.9 billion, down 40% year-on-year, with $1.2 billion in the US market and $745 million in the international market; At the peak of COVID-19 vaccines in 2022, the company was able to raise over $18 billion in a single year.

The oncology sector was the main driver of today's stock price rally. The intismeran autogene, a personalized tumor vaccine developed under the codename mRNA-4157, is used in combination with Merck's Keytruda for adjuvant treatment of fully resected stage IIB to IV melanoma.

It works more like a custom suit than a vaccine: first, it sequences mutations in the patient's own tumor, then designs and produces an mRNA agent tailored to that individual, teaching the immune system to recognize the unique markers of cancer cells.

So, what exactly is this company? It is not a vaccine factory, but a platform that translates biodata into mRNA sequences; COVID-19 was only the first product validation this platform was forced to undertake.

True irreplaceability comes from the triple stacking

The large-scale data and algorithm accumulation relied upon for sequence design, the complex chemical processes and GMP production standards behind lipid nanoparticle delivery systems, and the FDA's review criteria for mRNA drugs themselves were all established by precedents set by Moderna and BioNTech.

And the idea of "making it for each patient" is itself the toughest wall—the company is building a factory in Marlborough, Massachusetts dedicated to personalized oncology therapies, and this capacity can't be matched by buying equipment alone.

With a market cap of $45 billion, this matches the expected sales of $1.4 billion

Let's first look at a few glaring numbers

The company has lost $7.98 per share over the past twelve months, with a price-to-earnings ratio that cannot be calculated due to no profit, a return on equity of -46.59%, a price-to-sales ratio as high as 41.15, and a price-to-book ratio of 10.30.

In other words, the common valuation anchors for price-to-sales ratio, price-to-earnings ratio, and free cash flow yield either can't be calculated, or the results they do are simply 'the market is pricing the future, not the present.'

What is even more worth pondering is the value created on this day. Its market value jumped from about $25 billion to $69.62 billion, and in a single trading day, it suddenly grew by about $45 billion. But what does this $45 billion correspond to?

After releasing the data, Leerink Partners raised intismeran's sales potential by 2032 from $1.2 billion to about $1.4 billion. Barclays is more optimistic, expecting annual sales of about $3 billion for melanoma indications by 2035, with some analysts predicting that melanoma alone could exceed $6 billion.

Even with the most optimistic 6 billion annual sales, applying a daily increment of 45 billion yuan would require a price-to-sales ratio of more than seven times, and this is based on the full assumption that the drug is approved, a surge in volume is smooth, and personalized production can truly be scaled up. So is the market buying drugs today, or is it buying the bigger story of "platforms being validated"?

The answer on the cash side is relatively clear. By the end of Q2 2026, the company held $6.9 billion in cash and investments, but management's guidance for the year-end balance was $4.7 to $5.2 billion, meaning further consumption in the second half of the year will continue.

The good news is that the pace of money burning is slowing

The 2026 sales guidance has been lowered from $1.8 billion to $1.7 billion, R&D from $3 billion to $2.9 billion, and after deducting $900 million in litigation settlement expenses, full-year GAAP operating expenses are about $4.7 billion and cash costs about $4 billion, both of which are $200 million improvements over previous guidance.

As for whether the positive news has already been priced into the current stock price, there is a rather unforgiving fact: before the announcement, the 25 analysts unanimously rated it as hold, with an average target price of $52.95; After the news, Goldman Sachs raised its target price from 49 to 67, RBC raised it from 45 to 130, Brookline maintained its buy, and set a target price of 135 to close at $174.38, higher than the most aggressive among them.

Veterans in the concept stage have been pushed early by the market to commercialize them

From a financial structure perspective, Moderna is still in the proof-of-concept stage: three consecutive years of massive losses, GAAP net loss of $2.8 billion in 2025, diluted loss per share of $7.26, negative free cash flow, and all revenue dependent on a long-contracting COVID-19 vaccine market.

The seasonality of income is also extreme. Q1 2026 revenue was $389 million, but dropped sharply to $145 million in Q2. The company itself set a pace of about 15% of annual revenue in the first half and 85% in the second half, as respiratory disease peaks are concentrated in the third and fourth quarters.

The technical side tells a completely different story. The 50-day moving average was at $61.37, the 200-day moving average at $46.86, and the closing price was $174.38—the stock price has risen to more than three times the long-term moving average, a deviation extremely rare among large-cap stocks.

The market spent a trading day re-labeling the company from the "concept stage" as "about to commercialize." But the pace of fundamental realization is measured quarterly and annual, while the stock price was repriced in just six and a half hours. This time gap usually has to be filled step by step in the subsequent quarterly reports.

Half a length ahead, but the moat is speed, not walls

In the personalized neoantigen therapy track, Moderna is currently leading. The most direct competitor is BioNTech's autogene cevumeran, a collaboration with Genentech, which also offers mRNA therapies tailored to patients' tumor mutations, but its melanoma, pancreatic cancer, and colorectal cancer programs remain at Phase II.

In other words, the INTerpath-001 reading is not only Moderna's own victory, but also the first three-phase validation of the entire sector. The first company to obtain regulatory precedents often determines how high the threshold must be overcome by newcomers.

In the traditional vaccine business, the situation is quite the opposite. The COVID-19 vaccine market is dominated by Pfizer and BioNTech, while Moderna's market share and pricing power remain under pressure, which is the direct reason for its revenue dropping from 18 billion to 1.9 billion.

The flu thread has just opened a gap. mFLUSIVA is the first mRNA influenza vaccine approved for adults, covering adults aged 50 and above. Among those aged 65 and above, the accelerated approval pathway requires post-marketing research support, clinically showing a relative vaccine efficacy of 26.6% compared to the standard dose control group.

Its shortcomings are equally clear

The incidence of adverse reactions was higher than in the control group, with more common pain at the injection site and systemic symptoms. Although most were mild to moderate and resolved within a day or two, in a market where consumers could freely choose which injection to receive, the perceived effect could affect repeat purchases.

So, what exactly is Moderna's moat? Not just any product, but the speed and compliance of the assembly line "from sequencing data to delivery of a customized formulation"—the wall isn't high, but it takes a long time to climb.

A market that no one has yet to measure, and a market that is already shrinking

Currently, the ceiling on the tumor side can only be extended by extension. Inismeran has rolled out nine Phase II and Phase III clinical trials, covering non-small cell lung cancer, bladder cancer, renal cell carcinoma, pancreatic cancer, and gastric cancer, with melanoma being just the first domino of the dots.

Analysts' annual sales expectations for a single melanoma indication have ranged more than fourfold—from Leerink's $1.4 billion, Barclays' $3 billion, and then some institutions over $6 billion—this discrepancy alone shows that no one truly knows how big this market is, since no personalized cancer therapy has ever been commercialized.

The boundary on the airway side is much clearer and contracts inward. With COVID-19 vaccination rates declining year by year, policy support fading, and competitors setting tougher prices, management's full-year 2026 target is nothing more than "up to 10% revenue growth."

The real variable lies in the economics of personalized production

If each patient needs individual sequencing, design, and production separately, then the curve of capacity ramp-up, the rate of cost reduction per unit, and how much medical insurance payers are willing to pay to "reduce recurrence risk" — these three factors together determine whether the ceiling is 1.4 billion or 6 billion.

The platform has proven that this matter is more important than any single product

Those bullish on this stock are not buying melanoma, but rather the proposition that "mRNA can treat cancer" has received Phase III evidence for the first time:

▲ Bull Case

The most crucial set of numbers has not yet been released

The bearish reasons almost all point to one thing—the market paid $45 billion for an unreleased report card:

▼ Bear Case

From medical conferences to earnings season, there are four key time windows to keep an eye on

The next stock price rhythm is almost entirely determined by "when data turns into numbers." The following events are arranged in order:

•	Detailed data for phase III was released at an international medical conference: the timing is undecided, with a two-way impact, making it the event with the greatest risk exposure
•	Communication with regulators regarding filing submissions: progress is smooth and leans toward bullish positions in the coming months
•	mFLUSIVA will validate a surge in volume capacity of the flu line in the first commercial quarter of the 2026-2027 flu season: the third and fourth quarters
•	Q3 2026 Earnings Report: 85% of annual revenue was expected in the second half of the year, marking the first true test of the "up to 10% growth" guidance
•	The remaining eight INT Phase II and III trial readings were successively revealed: indications for lung cancer, bladder cancer, kidney cancer, and others

From $497 to $22, and then more than doubling in a single day

The stock price history of this company itself is an extreme example of emotion. On August 10, 2021, MRNA reached a historic high of $497.49, marking the tightest global COVID-19 vaccine demand, and the company subsequently generated over $18 billion in annual revenue that year.

After that, the collapse lasted five years. With vaccination rates declining, competition intensifying, and policy subsidies being phased out, revenue shrinking to $1.9 billion by 2025, with the stock price ranging from $22.28 to $85.60 over the past 52 weeks—a drop of over 95% from its peak.

Before August 19, its closing price was $62.96. After one trading day, this figure rose to $174.38, with a trading volume close to 185 million shares—more than nineteen times the three-month daily average of about 9.6 million shares. The intraday low was 114.46, and the high was 176.66, hovering near high levels almost all day.

It is worth noting the $58 gap between the opening price of $116.02 and the closing price of $174.38—the market did not immediately price at the opening and then move sideways at the start, but continued to raise prices throughout the day. This pattern could be a chain reaction where institutions are trying to identify new logic or a chain reaction of bears being forced to cover; the two look very similar on the market.

⚠️ Risk Notice • Detailed efficacy data for phase III have not been released, and actual benefits may be lower than expected for phase II • The proportion of short covering in the gains is unclear, and after the short squeeze subsides, the price may pull back sharply • The closing price was already above all published analyst targets, lacking capital for valuation relays • Whether the capacity and unit cost of personalized manufacturing can be scaled remains uncertain, with no commercial precedent • Revenue from its main respiratory vaccine business continues to shrink, and year-end cash balance guidance continues to decline

🟡 Neutral Platform verification is real, but the 45 billion yuan market value has been overdrawn by unpublished data and unimplemented commercialization.

💬 Discussion Don't chase highs, wait for detailed data to materialize. Its real-time buy and sell positions are posted on the official account via MRNA.

Data source

•	Source: NextPick real-time market snapshot + Moderna and Merck official announcements + company quarterly and annual earnings reports + SEC filings + mainstream financial media coverage.